Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Anti Angin** is a brand name medication primarily used for the symptomatic relief of angina pectoris and sore throat. It is a **combination drug** containing **carbocisteine** (a mucolytic agent that reduces mucus viscosity by altering disulfide bonds in sputum), **lidocaine hydrochloride** (a local anesthetic that blocks sodium channels to numb pain), and **cetylpyridinium chloride** (an antiseptic that disrupts bacterial cell membranes). This lozenge formulation is applied via the **sublingual/oral route** to provide local antitussive, analgesic, and antimicrobial effects in the oropharyngeal region, commonly marketed in regions like Eastern Europe and Asia for upper respiratory tract infections and anginal discomfort associated with throat inflammation. It is over-the-counter and not a systemic antianginal pharmaceutical like nitrates or beta-blockers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anti Angin.